Bronchopulmonary Dysplasia Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - ResearchAndMarkets.com

DUBLIN--()--The "Bronchopulmonary Dysplasia Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

Bronchopulmonary Dysplasia Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.

Bronchopulmonary Dysplasia (BPD) Analysis report covers 6 drugs currently in different phases of development. Bronchopulmonary Dysplasia (BPD) is a chronic respiratory disease affecting preature newborns and infants. BPD generally occurs in severely ill infants who have been on ventilator or have received oxygen for long period of time. Symptoms of BPD are cyanosis, constant and persistent cough, rapid and shallow breathing and shortness of breath. BP is diagnosed using chest x-ray, blood tests, Pulse oximetry and echocardiography. Currently medications such as bronchodilators (Albuterol, to open up airways), Diuretics (to reduce fluid build-up in the lungs) and anti-inflammatory are used for the treatment of the disease.

The report provides Bronchopulmonary Dysplasia (BPD) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Companies Mentioned

  • Airway Therapeutics, LLC
  • Medipost Co., Ltd.
  • Meridigen Biotechnology
  • Shire Plc
  • Therabron Therapeutics
  • United Therapeutics Corporation

Key Topics Covered:

1. Introduction

2. Disease Overview

3. Executive Summary

4. Market Dynamics

5. Pipeline Analysis/Outlook

6. Company profiling

For more information about this report visit https://www.researchandmarkets.com/research/9lv5rs/bronchopulmonary?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs, Clinical Trials

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs, Clinical Trials